Medrx Co

Medrx Co OCF Margin

The Operating Cash Flow Margin of Medrx Co (4586.T) as of Nov 19, 2026 is -693.38 %. In the previous year, Operating Cash Flow Margin was -311.34 % — a change of 122.71% (lower).

OCF Margin

-693.38 %

YoY

122.71%

Last updated:

Operating Cash Flow Margin of Medrx Co is 2025 -693.38 % . Operating Cash Flow Margin of Medrx Co was 2024 -311.34 % . It decreases by 122.71% lower compared to the previous year.

The Medrx Co OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
-15,015.45 JPY
Jan 1, 2019
-910.72 JPY
Jan 1, 2020
-856.14 JPY
Jan 1, 2021
-11,062.13 JPY
Jan 1, 2022
-1,804.40 JPY
Jan 1, 2023
-3,091.35 JPY
Jan 1, 2024
-311.34 JPY
Jan 1, 2025
-693.38 JPY
The Medrx Co OCF Margin history
YEAROCF MarginYoY
-693.38 %+122.71%
-311.34 %-89.93%
-3,091.35 %+71.32%
-1,804.40 %-83.69%
-11,062.13 %+1,192.09%
-856.14 %-5.99%
-910.72 %-93.93%
-15,015.45 %+3,383.76%
-431.01 %-92.07%
-5,438.44 %+159.23%
-2,097.89 %-40.82%
-3,545.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Operating Cash Flow Margin of Medrx Co is -693.38 % in 2025.

Operating Cash Flow Margin of Medrx Co changed from -311.34 % to -693.38 %, representing a 122.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Medrx Co since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Medrx Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Medrx Co

All Key Metrics — Medrx Co